Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq:…
Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell
Celebrates Indian Independence Day by Honoring the US-India Innovation PartnershipCAMBRIDGE, Mass.--(BUSINESS WIRE)--$HIND--Vyome…
Guidelines for Osstem Implants, Implant Fracture and Peripheral Diseases are Presented
Listed in the prestigious international academic journal, MDPI 'Prosthesis' SEOUL, South Korea,…
Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort
NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker…
FDA Approves Apellis EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
Proven efficacy across all three key markers of disease—68% reduction in proteinuria,…
Scaling Self-Care Can Be a Game-Changer in Global Fight Against Non-Communicable Diseases
Ahead of the upcoming UN General Assembly to set a new vision…
Life Biosciences Announces Research Collaboration with SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS) to Expand Pipeline of Cellular Rejuvenation Therapies
Collaboration in Singapore aims to further expand the broad potential of Life…
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 18, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif.,…
Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital
CHICAGO, July 16, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a newly formed…
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or…